Literature DB >> 15358555

Truncated KCNQ1 mutant, A178fs/105, forms hetero-multimer channel with wild-type causing a dominant-negative suppression due to trafficking defect.

Yoshiyasu Aizawa1, Kazuo Ueda, Long-Mei Wu, Natsuko Inagaki, Takeharu Hayashi, Megumi Takahashi, Masaaki Ohta, Seiko Kawano, Yuji Hirano, Michio Yasunami, Yoshifusa Aizawa, Akinori Kimura, Masayasu Hiraoka.   

Abstract

We identified a novel mutation Ala178fs/105 missing S3-S6 and C-terminus portions of KCNQ1 channel. Ala178fs/105-KCNQ1 expressed in COS-7 cells demonstrated no current expression. Co-expression with wild-type (WT) revealed a dominant-negative effect, which suggests the formation of hetero-multimer by mutant and WT. Confocal laser microscopy displayed intracellular retention of Ala178fs/105-KCNQ1 protein. Co-expression of the mutant and WT also increased intracellular retention of channel protein compared to WT alone. Our findings suggest a novel mechanism for LQT1 that the truncated S1-S2 KCNQ1 mutant forms hetero-multimer and cause a dominant-negative effect due to trafficking defect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358555     DOI: 10.1016/j.febslet.2004.08.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

Review 1.  Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking.

Authors:  William T Harkcom; Geoffrey W Abbott
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-08

2.  Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene.

Authors:  Arthur J Moss; Wataru Shimizu; Arthur A M Wilde; Jeffrey A Towbin; Wojciech Zareba; Jennifer L Robinson; Ming Qi; G Michael Vincent; Michael J Ackerman; Elizabeth S Kaufman; Nynke Hofman; Rahul Seth; Shiro Kamakura; Yoshihiro Miyamoto; Ilan Goldenberg; Mark L Andrews; Scott McNitt
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

3.  The GABRG2 mutation, Q351X, associated with generalized epilepsy with febrile seizures plus, has both loss of function and dominant-negative suppression.

Authors:  Jing-Qiong Kang; Wangzhen Shen; Robert L Macdonald
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

4.  A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome.

Authors:  Yoshiyasu Aizawa; Kazuo Ueda; Fabiana Scornik; Jonathan M Cordeiro; Yuesheng Wu; Mayurika Desai; Alejandra Guerchicoff; Yasutoshi Nagata; Yoshito Iesaka; Akinori Kimura; Masayasu Hiraoka; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2007-07-26

5.  Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.

Authors:  Peter J Schwartz; Cristina Moreno; Maria-Christina Kotta; Matteo Pedrazzini; Lia Crotti; Federica Dagradi; Silvia Castelletti; Kristina H Haugaa; Isabelle Denjoy; Maria A Shkolnikova; Paul A Brink; Marshall J Heradien; Sandrine R M Seyen; Roel L H M G Spätjens; Carla Spazzolini; Paul G A Volders
Journal:  Eur Heart J       Date:  2021-12-07       Impact factor: 29.983

6.  Spinocerebellar ataxia type 19/22 mutations alter heterocomplex Kv4.3 channel function and gating in a dominant manner.

Authors:  Anna Duarri; Meng-Chin A Lin; Michiel R Fokkens; Michel Meijer; Cleo J L M Smeets; Esther A R Nibbeling; Erik Boddeke; Richard J Sinke; Harm H Kampinga; Diane M Papazian; Dineke S Verbeek
Journal:  Cell Mol Life Sci       Date:  2015-04-09       Impact factor: 9.261

Review 7.  Molecular pathogenesis of long QT syndrome type 1.

Authors:  Jie Wu; Wei-Guang Ding; Minoru Horie
Journal:  J Arrhythm       Date:  2016-01-27

8.  Disruption of a Conservative Motif in the C-Terminal Loop of the KCNQ1 Channel Causes LQT Syndrome.

Authors:  Maria Karlova; Denis V Abramochkin; Ksenia B Pustovit; Tatiana Nesterova; Valery Novoseletsky; Gildas Loussouarn; Elena Zaklyazminskaya; Olga S Sokolova
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.